About Tr1X
Tr1X focuses on developing cellular immunotherapies aimed at treating autoimmune and inflammatory diseases. The company uses a proprietary platform to create cell therapy products that help to rebalance the immune system and restore its natural balance, which is essential for long-term health. Unlike many other companies in the biopharmaceutical sector, Tr1X specializes in first-in-class therapies that target the underlying causes of immune system disorders rather than just alleviating symptoms. The goal of Tr1X is to provide advanced therapeutic solutions that lead to lasting tolerance in patients, improving their quality of life.
San Diego, CaliforniaHeadquarters
2018Year Founded
$73MTotal Funding
SERIES_ACompany Stage
Biotechnology, HealthcareIndustries
11-50Employees
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
401(k) Company Match
Flexible Work Hours
Stock Options
Performance Bonus
Risks
Emerging competition in allogeneic Treg therapy could impact Tr1X's market share.
High manufacturing costs may pose financial risks for Tr1X.
Regulatory hurdles could delay Tr1X's product development and market entry.
Differentiation
Tr1X uses a proprietary platform for novel cellular immunotherapies.
The company focuses on allogeneic regulatory T-cell therapies for autoimmune diseases.
Tr1X's TRX103 is the first allogeneic engineered Tr1 regulatory T cell product.
Upsides
FDA clearance for TRX103 IND boosts Tr1X's credibility and market potential.
$75M Series A funding supports rapid development of Tr1X's therapies.
Growing autoimmune therapeutics market offers significant opportunities for Tr1X's products.
Funding
Total raised$72.95 M
Latest valuation$375.00 M
StageSERIES_A
SERIES A
12/31/2023$75
$375.00 M